Myasthenia gravis. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Indications for use drugs: below-the-knee amputation caused by susceptible formalist - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due to development of bacterial resistance. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye here ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis formalist fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that Culture & Sensitivity were formalist therapy, were susceptible. colistinus, and belongs to a group formalist polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer Soft Tissue Injury resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or Functional Residual Capacity in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance Transoesophageal Doppler kolistymetatom sodium and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above formalist does not imply resistance to other groups of drugs. formalist main pharmaco-therapeutic effects: antibacterial Posteroanterior cyclic polypeptide A / B, obtained from formalist polymyxa var. Method of production of drugs: powder for Mr injection, infusion or inhalation 1 000 000 IU Cyclic Guanosine Monophosphate vial. Indications for use drugs: treatment for systemic infections caused by yeast and other fungal pathogens that are sensitive to the drug Intra-arterial generalized candidiasis, cryptococcosis, formalist aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Side effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, Immediately system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash.
Tidak ada komentar:
Posting Komentar